Business Description
Collegium Pharmaceutical Inc
NAICS : 325412
SIC : 2834
ISIN : US19459J1043
Description
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.14 | |||||
| Equity-to-Asset | 0.14 | |||||
| Debt-to-Equity | 3.73 | |||||
| Debt-to-EBITDA | 2.52 | |||||
| Interest Coverage | 2.74 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 1.01 | |||||
| Beneish M-Score | -2.45 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15.4 | |||||
| 3-Year EBITDA Growth Rate | 30 | |||||
| 3-Year EPS without NRI Growth Rate | 93.1 | |||||
| 3-Year Book Growth Rate | 4.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 8.79 | |||||
| Future 3-5Y Total Revenue Growth Rate | 11 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 28.75 | |||||
| 9-Day RSI | 35.71 | |||||
| 14-Day RSI | 37.91 | |||||
| 6-1 Month Momentum % | -5.43 | |||||
| 12-1 Month Momentum % | -0.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.97 | |||||
| Quick Ratio | 0.88 | |||||
| Cash Ratio | 0.26 | |||||
| Days Inventory | 52.96 | |||||
| Days Sales Outstanding | 115.53 | |||||
| Days Payable | 7.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 2.7 | |||||
| Shareholder Yield % | 6.73 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 62.36 | |||||
| Operating Margin % | 32.29 | |||||
| Net Margin % | 14.78 | |||||
| FCF Margin % | 32.11 | |||||
| ROE % | 42.29 | |||||
| ROA % | 7.23 | |||||
| ROIC % | 15.27 | |||||
| ROC (Joel Greenblatt) % | 923.59 | |||||
| ROCE % | 25.9 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 12.51 | |||||
| Forward PE Ratio | 4.43 | |||||
| PE Ratio without NRI | 4.67 | |||||
| Price-to-Owner-Earnings | 16.71 | |||||
| PS Ratio | 2.17 | |||||
| PB Ratio | 4.01 | |||||
| Price-to-Free-Cash-Flow | 7.11 | |||||
| Price-to-Operating-Cash-Flow | 7.06 | |||||
| EV-to-EBIT | 8.62 | |||||
| EV-to-EBITDA | 4.94 | |||||
| EV-to-Revenue | 2.86 | |||||
| EV-to-Forward-Revenue | 2.38 | |||||
| EV-to-FCF | 8.9 | |||||
| Price-to-Projected-FCF | 1.17 | |||||
| Earnings Yield (Greenblatt) % | 11.6 | |||||
| FCF Yield % | 20.47 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:COLL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Collegium Pharmaceutical Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 599.245 | ||
| EPS (TTM) ($) | 2.33 | ||
| Beta | 0.76 | ||
| Volatility % | 38.33 | ||
| 14-Day RSI | 37.91 | ||
| 14-Day ATR ($) | 1.177227 | ||
| 20-Day SMA ($) | 30.4215 | ||
| 12-1 Month Momentum % | -0.3 | ||
| 52-Week Range ($) | 28.965 - 42.2873 | ||
| Shares Outstanding (Mil) | 32.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Collegium Pharmaceutical Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Collegium Pharmaceutical Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Collegium Pharmaceutical Inc Frequently Asked Questions
What is Collegium Pharmaceutical Inc(COLL)'s stock price today?
The current price of COLL is $29.12. The 52 week high of COLL is $42.29 and 52 week low is $28.97.
When is next earnings date of Collegium Pharmaceutical Inc(COLL)?
The next earnings date of Collegium Pharmaceutical Inc(COLL) is 2025-02-21 Est..
Does Collegium Pharmaceutical Inc(COLL) pay dividends? If so, how much?
Collegium Pharmaceutical Inc(COLL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers